Federated Hermes Inc. reduced its holdings in IQVIA Holdings Inc. (NYSE:IQV – Free Report) by 9.8% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 171,525 shares of the medical research company’s stock after selling 18,688 shares during the period. Federated Hermes Inc.’s holdings in IQVIA were worth $39,687,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors have also modified their holdings of IQV. HighTower Advisors LLC boosted its position in IQVIA by 2.4% during the 1st quarter. HighTower Advisors LLC now owns 5,055 shares of the medical research company’s stock valued at $1,168,000 after purchasing an additional 118 shares during the period. Prudential PLC acquired a new position in shares of IQVIA during the first quarter valued at $741,000. Baird Financial Group Inc. grew its position in shares of IQVIA by 2.3% during the first quarter. Baird Financial Group Inc. now owns 99,566 shares of the medical research company’s stock worth $23,021,000 after acquiring an additional 2,201 shares during the last quarter. Parkside Financial Bank & Trust lifted its position in IQVIA by 59.0% in the 1st quarter. Parkside Financial Bank & Trust now owns 388 shares of the medical research company’s stock valued at $90,000 after purchasing an additional 144 shares during the last quarter. Finally, Covestor Ltd boosted its stake in IQVIA by 82.2% during the 1st quarter. Covestor Ltd now owns 554 shares of the medical research company’s stock valued at $128,000 after purchasing an additional 250 shares during the period. 89.62% of the stock is owned by institutional investors and hedge funds.
IQVIA Trading Up 0.4 %
Shares of NYSE:IQV opened at $228.09 on Friday. IQVIA Holdings Inc. has a 1-year low of $167.42 and a 1-year high of $261.73. The company has a 50 day moving average price of $244.82 and a 200 day moving average price of $221.87. The stock has a market capitalization of $41.40 billion, a price-to-earnings ratio of 31.29, a PEG ratio of 2.21 and a beta of 1.50. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.86 and a current ratio of 0.86.
IQVIA (NYSE:IQV – Get Free Report) last posted its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.82 by $0.02. IQVIA had a return on equity of 29.32% and a net margin of 9.06%. The firm had revenue of $3.87 billion for the quarter, compared to the consensus estimate of $3.80 billion. During the same quarter in the previous year, the company earned $2.54 EPS. The business’s revenue for the quarter was up 3.5% compared to the same quarter last year. On average, research analysts anticipate that IQVIA Holdings Inc. will post 10.11 EPS for the current fiscal year.
Insider Activity
In related news, insider Ari Bousbib sold 31,678 shares of the company’s stock in a transaction on Friday, March 1st. The stock was sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, insider Ari Bousbib sold 31,678 shares of the business’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $250.53, for a total transaction of $7,936,289.34. Following the transaction, the insider now directly owns 796,752 shares of the company’s stock, valued at $199,610,278.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Kevin C. Knightly sold 8,607 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $250.17, for a total transaction of $2,153,213.19. Following the completion of the sale, the insider now owns 5,251 shares of the company’s stock, valued at approximately $1,313,642.67. The disclosure for this sale can be found here. Insiders sold 41,285 shares of company stock worth $10,331,003 over the last quarter. Corporate insiders own 1.60% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on IQV shares. Evercore ISI lifted their price target on IQVIA from $255.00 to $265.00 and gave the company a “market outperform” rating in a report on Thursday, February 15th. Barclays boosted their price target on IQVIA from $260.00 to $265.00 and gave the stock an “overweight” rating in a research report on Thursday, February 15th. Robert W. Baird raised their price target on IQVIA from $226.00 to $251.00 and gave the company a “neutral” rating in a report on Thursday, February 15th. Guggenheim downgraded shares of IQVIA from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Finally, Leerink Partnrs reissued an “outperform” rating on shares of IQVIA in a research note on Monday, February 26th. Three analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $256.80.
Read Our Latest Analysis on IQVIA
IQVIA Company Profile
(Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Featured Stories
Want to see what other hedge funds are holding IQV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IQVIA Holdings Inc. (NYSE:IQV – Free Report).
Receive News & Ratings for IQVIA Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for IQVIA and related companies with MarketBeat.com’s FREE daily email newsletter.